What a GLP-1 Actually Costs

I spend more clinic time on this than on any pharmacology question, and I have never found an honest, non-promotional account of it written by a clinician. So here is mine.

A note on numbers before we start. Pricing in this category changes faster than any article can track — list prices, direct-purchase programmes, and formulary decisions have all moved repeatedly since these drugs launched. I have used ranges rather than precise figures deliberately. Verify current pricing with the manufacturer’s own programme and with your plan. The part of this piece with a long shelf life is the framework, not the figures.

Four price realities

People discuss “the cost” as though there is one. There are four, and they differ by roughly an order of magnitude.

1. Covered by insurance. You pay a copay — often modest, sometimes tiered, occasionally with a coinsurance percentage that makes it much worse than it sounds. This is the best case and it is less common than you would think, because a large share of employer plans exclude weight-loss drugs entirely.

2. Manufacturer direct-purchase, self-pay. Both major manufacturers now run cash-pay programmes selling directly to patients without insurance. These are substantially cheaper than retail pharmacy — typically in the low hundreds per month rather than four figures — and they are FDA-approved product. For most uninsured patients this is the route to check first, and many people do not know it exists.

3. Cash retail pharmacy. List price with no programme and no coverage. Generally around a thousand dollars a month or more. Almost nobody should be paying this, and if you are, it is worth ten minutes finding out why.

4. Compounded. Cheapest, and the one I have the most to say about below.

Why you were denied, and what to do about it

Denials feel clinical. Most of them are not.

First: find out which kind of denial it is

This single question changes everything and almost nobody asks it. Get the reason in writing.

“Weight-loss medications are excluded under this plan.” This is a benefit design exclusion, not a clinical judgement, and no amount of evidence about your BMI will change it. Your routes are a formulary exception request, a different covered indication, or your employer’s benefits committee — genuinely, if enough employees ask, plans change at renewal.

“Criteria not met.” This is procedural and it is usually fixable. The plan wants a BMI threshold documented, or a comorbidity coded, or a documented trial of lifestyle intervention or a preferred alternative drug, and one of those is missing from the submission. Ask which one.

“Not medically necessary.” This is the one worth appealing properly.

Write the appeal around the indication with outcome data

Here is the thing I have learned over three years of writing these letters, and it changed my success rate substantially.

An appeal that says my patient would like to lose weight is a weak document. An appeal that says my patient has established cardiovascular disease, and SELECT — a randomised trial of 17,604 patients — showed a 20% reduction in major adverse cardiovascular events in precisely this population is a different document entirely. It is no longer a request for a cosmetic benefit. It is a request for cardiovascular therapy with hard-endpoint evidence.

The same logic applies elsewhere. Obstructive sleep apnea has SURMOUNT-OSA. Type 2 diabetes has its own indications and its own outcome trials. Chronic kidney disease with type 2 diabetes has FLOW.

Include, specifically: the diagnosis codes, the BMI and comorbidities with dates, documented prior attempts and why they failed, and a direct citation to the relevant trial. Ask your prescriber to escalate to a peer-to-peer review if the written appeal fails — a conversation between two physicians resolves a meaningful share of these.

The compounding question

I am not going to lecture anybody about the impossible position that drug pricing puts patients in. The gap between what these drugs cost and what people can pay is a policy failure, and the people caught in it did not create it.

What I will say plainly, as clinical information rather than moralising:

• Compounded semaglutide and tirzepatide are not FDA-approved products. They have not been through the review that establishes potency, purity, and consistency.
• Some products sold have been salt forms — semaglutide sodium, semaglutide acetate — which are not the molecule studied in any of the trials above.
• Dosing errors have caused documented harm. Vials and syringes require the patient to calculate and draw a dose, and units-versus-milligrams confusion has put people in emergency departments.
• The trial results in the evidence table were produced with specific approved products at specific doses. They do not automatically transfer.

If you are using a compounded product, please do it under the supervision of a clinician who knows you are, and please be certain you understand your dose in milligrams.

The analysis nobody publishes: cost per point

Here is a way of thinking about this that I have not seen written down, and that I find clarifies decisions.

The relevant unit is not dollars per month. It is dollars per percentage point of body weight lost, per year of treatment — and, more importantly, per year of sustained treatment.

Take the trial data. Semaglutide 2.4 mg produced a mean 14.9% loss over 68 weeks. Tirzepatide at maximum tolerated dose produced 20.2% over 72 weeks in the head-to-head. Now put a monthly cost against each and divide.

Do that arithmetic with your own actual numbers and two things fall out immediately.

First: the direct-purchase route changes the ranking. A drug that is nominally superior on effect size can be considerably worse on cost per point if one route is available to you and the other is not. Effect size is one input, not the answer.

Second, and much more important: the denominator is years, not months. A course you abandon at month five because you cannot afford month six does not deliver the 20% — it delivers whatever you had at month five, and then the regain data takes most of that back within a year.

Which produces the conclusion I now give patients: the best drug is frequently the one you can still afford in month twenty-four. An adequate treatment sustained beats a superior treatment abandoned, and it is not close.

Making the prescription work harder

The other half of cost-effectiveness gets almost no attention, and it is the half you control.

If you are spending real money on this every month, the return on that spend is determined by three things: staying on it, protecting lean mass, and not quitting during a bad week. None of those are pharmacology. All of them are follow-through.

This is the practical argument for structure. I use the Zenday App to keep dose, side effects, and protein in one place, and the reason I keep recommending it in this specific context is the cost framing: side effects are among the most common reasons people abandon treatment, and an abandoned treatment is a total loss of everything spent to that point. A tool that helps you get through month two, and that stops protein quietly drifting down in month five, is not an accessory to an expensive prescription. It is what determines whether the expensive prescription pays for itself.

The questions to ask this week

If you are trying to work out your own situation, in order:

1. Does my plan exclude weight-loss drugs? Ask HR or the plan document, not the pharmacy.
2. If not, what exactly are the coverage criteria? Get them in writing and check which one you fail.
3. Do I have a comorbidity with outcome data behind it? Cardiovascular disease, sleep apnea, type 2 diabetes, chronic kidney disease.
4. What does the manufacturer’s direct-purchase programme cost at my dose?
5. What would happen in January if my employer changed plans? Answer this while things are going well, not in the week the pharmacy tells you the price changed.

Supply is the other way a prescription stops working, and it fails differently from a denial — what to do in a GLP-1 shortage covers the restart plan worth agreeing before you need it.

One more cost worth naming, because it is not financial: a poor prescriber is expensive in a different currency. What proper care includes, and the red flags that indicate its absence, are in how to choose a GLP-1 prescriber. The strongest coverage arguments also now include obstructive sleep apnea, which has both an approved indication and trial evidence behind it — GLP-1s and sleep apnea.